Per Copilot:
[i]Q: what are the criteria that major cancer centers use to accept – or reject – patients?
A: Major cancer centers don’t “accept” or “reject” patients the way insurance companies do, but they do apply a set of medical, logistical, and safety‑driven criteria—especially when deciding whether a patient can receive specialized treatments or enter a clinical trial. The criteria fall into a few consistent categories across major centers (NCI‑designated centers, academic hospitals, and large international oncology institutes).
Core criteria used to accept or decline patients for treatment or trials:
- Performance status (How sick the patient is)
Centers evaluate how well a patient can perform daily activities using scales like ECOG or Karnofsky.
Historically, low performance status often led to exclusion, but FDA guidance now warns against rigid cutoffs, noting that some patients improve once treated.
Patients who are bedbound or unable to perform basic self‑care may be declined for intensive therapies or clinical trials because of safety concerns.
- Organ function requirements
Most advanced treatments (chemo, immunotherapy, targeted agents) require:
Adequate liver function
Adequate kidney function
Adequate bone marrow reserves
Acceptable cardiac function
(These are measured through lab values and imaging).
FDA guidance emphasizes that lab thresholds should be scientifically justified, not arbitrary.
- Washout periods and medication conflicts
Centers may decline patients who:
Recently received another cancer therapy
Are taking medications that interact with the proposed treatment
FDA now encourages case‑by‑case justification rather than blanket exclusions.
- Disease stage and type
Some centers specialize in:
Early‑stage surgical oncology
Highly complex metastatic disease
Specific cancer types (e.g., sarcoma, pediatric cancers)
Patients may be redirected if the center does not treat their cancer type or stage.
- Clinical trial eligibility criteria
Trials have strict inclusion/exclusion rules:
Specific mutation status (e.g., EGFR, BRCA)
Prior lines of therapy
No active infections
No uncontrolled comorbidities
These criteria are often the most common reason patients are rejected from major centers when seeking experimental therapy. FDA and NCI have been modernizing these criteria to reduce unnecessary exclusions.
- Insurance coverage and financial clearance
While not a medical criterion, major centers often decline patients when:
Insurance denies coverage for the proposed treatment
The center is out‑of‑network
Insurance denials are extremely common—34% of cancer patients experience at least one denial, often delaying care by 27 days.
- Logistical feasibility
Centers may decline patients if:
They cannot travel frequently enough for treatment
They cannot meet monitoring requirements
They lack adequate home support for high‑risk therapies (e.g., CAR‑T)
- Safety concerns
Patients may be rejected if:
They have uncontrolled infections
They have severe organ failure
They are too frail for anesthesia or chemotherapy
These decisions are usually made by multidisciplinary tumor boards.
Why these criteria matter:
Major cancer centers aim to:
Protect patients from treatments that could be dangerous
Ensure trial results are scientifically valid
Allocate limited resources (ICU beds, infusion slots, specialized staff)
Comply with regulatory and ethical standards
Recent FDA guidance stresses that overly restrictive criteria harm patients and reduce trial diversity, pushing centers to broaden access.
If you want, I can go deeper into how specific centers (MD Anderson, Memorial Sloan Kettering, Mayo Clinic, etc.) apply these criteria, or explain which criteria matter most for your situation. Would you like a breakdown by specific cancer center or by treatment type?[/i]
A look at what Copilot claims are real-world criteria that major cancer treatment centers use to evaluate whether to accept or reject potential patients.
I suppose they are “reasonable” criteria, more or less, or as much so as one can expect them to be, although I don’t suppose it would be all that difficult to find and present a case that doesn’t fit the “criteria,” but which would seem to cry out for acceptance.
But I also suppose that the decision committees, or whoever it is that makes these final decisions, do the best they can.